| PPCB Stock | | | USD 0.0002 0.0001 33.33% |
CEO
Mr. James Nathanielsz is Chief Executive Officer, Treasurer, Secretary, Director of Propanc Health Group Corporationration James Nathanielsz has served as a director since inception. Mr. Nathanielsz has served as a director and Chief Executive Officer of our Australian company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an antiinfective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the CoFounder of our Australian company and for his experience in RD and manufacturing and distribution
| Age | 49 |
| Phone | 61 3 9882 0780 |
| Web | https://www.propanc.com |
Nathanielsz graduated with a Bachelor of Applied Science, majoring in Biochemistry/Applied Chemistry and subsequently with a Master of Entrepreneurship & Innovation from Swinburne University of Technology in Melbourne, Australia.
Propanc Biopharma Management Efficiency
The company has return on total asset
(ROA) of
(13.0742) % which means that it has lost $13.0742 on every $100 spent on assets. This is way below average. Propanc Biopharma's management efficiency ratios could be used to measure how well Propanc Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.
Propanc Biopharma currently holds 1.1
M in liabilities. Debt can assist Propanc Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Propanc Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Propanc Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Propanc to invest in growth at high rates of return. When we think about Propanc Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people. Propanc Biopharma [PPCB] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Propanc Biopharma Management Team
Elected by the shareholders, the Propanc Biopharma's board of directors comprises two types of representatives: Propanc Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Propanc. The board's role is to monitor Propanc Biopharma's management team and ensure that shareholders' interests are well served. Propanc Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Propanc Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Propanc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Propanc Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Propanc Pink Sheet
Propanc Biopharma financial ratios help investors to determine whether Propanc Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Propanc with respect to the benefits of owning Propanc Biopharma security.